Alpha2 adrenergic agonists for the management of opioid withdrawal

Lofexidine versus clonidine for mitigation of opioid withdrawal symptoms: A systematic review

“…This review showed that lofexidine is efficacious and comparable to clonidine treatment in mitigating opioid withdrawal symptoms. Our findings are similar to those of Gowing et al, 13 who examined multiple a-2-receptor agonists for managing opioid withdrawal. With the recent approval for lofexidine use in the United States and with the increased public concern surrounding the opioid crisis, it is clear that we need to understand interventions to manage opioid use disorder better.…”

Lofexidine versus clonidine for mitigation of opioid withdrawal symptoms: A systematic review

“…This review showed that lofexidine is efficacious and comparable to clonidine treatment in mitigating opioid withdrawal symptoms. Our findings are similar to those of Gowing et al, 13 who examined multiple a-2-receptor agonists for managing opioid withdrawal. With the recent approval for lofexidine use in the United States and with the increased public concern surrounding the opioid crisis, it is clear that we need to understand interventions to manage opioid use disorder better.…”

A Novel Role of Dexmedetomidine in the Modulation of Morphine Reward Memory via γ-Aminobutyric Acid Transporter-1

“…Chronic opioid exposure suppresses LC noradrenergic neuronal activity, and immediate cessation leads to rebound hyperactivity of these neurons, causing typical withdrawal symptoms such as anxiety, agitation, and hypertension. 30 , 31 In line with previous studies, 17 – 19 , 32 we found that both systemic and intra-LC administration of Dex, similar to clonidine and lofexidine, can alleviate morphine withdrawal symptoms. Importantly, our data revealed a key distinction between Dex and other α 2 agonists.…”

Safety and Efficacy of Lofexidine for Medically Managed Opioid Withdrawal: A Randomized Controlled Clinical Trial

“…Our efficacy results were also consistent with a recent meta-analysis of randomized, controlled trials of a 2 -adrenergic agonists for treatment of OWS, which concluded that lofexidine is safe and effective for OWS management (Gowing et al, 2016).…”

Lofexidine versus clonidine for mitigation of opioid withdrawal symptoms: A systematic review

“…This review showed that lofexidine is efficacious and comparable to clonidine treatment in mitigating opioid withdrawal symptoms. Our findings are similar to those of Gowing et al, 13 who examined multiple a-2-receptor agonists for managing opioid withdrawal. With the recent approval for lofexidine use in the United States and with the increased public concern surrounding the opioid crisis, it is clear that we need to understand interventions to manage opioid use disorder better.…”

A Novel Role of Dexmedetomidine in the Modulation of Morphine Reward Memory via γ-Aminobutyric Acid Transporter-1

“…Chronic opioid exposure suppresses LC noradrenergic neuronal activity, and immediate cessation leads to rebound hyperactivity of these neurons, causing typical withdrawal symptoms such as anxiety, agitation, and hypertension. 30 , 31 In line with previous studies, 17 – 19 , 32 we found that both systemic and intra-LC administration of Dex, similar to clonidine and lofexidine, can alleviate morphine withdrawal symptoms. Importantly, our data revealed a key distinction between Dex and other α 2 agonists.…”

Safety and Efficacy of Lofexidine for Medically Managed Opioid Withdrawal: A Randomized Controlled Clinical Trial

“…Our efficacy results were also consistent with a recent meta-analysis of randomized, controlled trials of a 2 -adrenergic agonists for treatment of OWS, which concluded that lofexidine is safe and effective for OWS management (Gowing et al, 2016).…”

Lofexidine versus clonidine for mitigation of opioid withdrawal symptoms: A systematic review

“…This review showed that lofexidine is efficacious and comparable to clonidine treatment in mitigating opioid withdrawal symptoms. Our findings are similar to those of Gowing et al, 13 who examined multiple a-2-receptor agonists for managing opioid withdrawal. With the recent approval for lofexidine use in the United States and with the increased public concern surrounding the opioid crisis, it is clear that we need to understand interventions to manage opioid use disorder better.…”

A Novel Role of Dexmedetomidine in the Modulation of Morphine Reward Memory via γ-Aminobutyric Acid Transporter-1

“…Chronic opioid exposure suppresses LC noradrenergic neuronal activity, and immediate cessation leads to rebound hyperactivity of these neurons, causing typical withdrawal symptoms such as anxiety, agitation, and hypertension. 30 , 31 In line with previous studies, 17 – 19 , 32 we found that both systemic and intra-LC administration of Dex, similar to clonidine and lofexidine, can alleviate morphine withdrawal symptoms. Importantly, our data revealed a key distinction between Dex and other α 2 agonists.…”

Safety and Efficacy of Lofexidine for Medically Managed Opioid Withdrawal: A Randomized Controlled Clinical Trial

“…Our efficacy results were also consistent with a recent meta-analysis of randomized, controlled trials of a 2 -adrenergic agonists for treatment of OWS, which concluded that lofexidine is safe and effective for OWS management (Gowing et al, 2016).…”